Hope Biomedical Inc is a Taiwan-based biotechnology company headquartered in Taipei, Taiwan, specializing in stem cell therapy and regenerative medicine approaches for neurodegenerative diseases, including Parkinson's disease (PD)[1]. Founded in 2006, Hope Biomedical focuses on developing mesenchymal stem cell (MSC)-based therapies that aim to provide neuroprotective and immunomodulatory effects for patients with progressive neurological disorders[2].
| Attribute | Details |
|---|---|
| Headquarters | Taipei, Taiwan |
| Founded | 2006 |
| Ticker | Taiwan OTC: 1783.TT |
| Focus Areas | Stem cell therapy, regenerative medicine, neurodegenerative diseases |
| Technology Platform | Mesenchymal stem cell (MSC) therapy |
| Website | hopebiomed.com |
Hope Biomedical's core technology platform utilizes mesenchymal stem cells derived from various sources[3]:
The company's MSC platform offers several advantages for neurodegenerative disease treatment[4]:
Hope Biomedical maintains advanced manufacturing capabilities[5]:
Hope Biomedical's PD program focuses on delivering MSC-based therapies that address multiple pathological features of Parkinson's disease[6]:
| Program | Indication | Stage | Notes |
|---|---|---|---|
| MSC-PD-001 | Parkinson's Disease | Preclinical/IND-enabling | MSC therapy for motor symptoms |
| MSC-PD-002 | Parkinson's Disease | Research | Novel formulation |
MSC therapy for Parkinson's disease has demonstrated promise in preclinical models[7]:
The company is pursuing several clinical development pathways[8]:
Hope Biomedical is also developing MSC therapies for stroke rehabilitation:
The company is exploring MSC-based approaches for spinal cord injury:
MSC therapies for various autoimmune conditions are also in development.
Hope Biomedical collaborates with leading Taiwanese research institutions[9]:
International collaborations include partnerships with Japanese and Korean biotechnology companies.
Hope Biomedical competes in the global MSC therapy space against[10]:
Taiwan's advantages in MSC development include strong academic research in stem cell biology, favorable regulatory environment for cell therapy, and cost-effective manufacturing capabilities.
The company is navigating regulatory pathways in Taiwan (TFDA), Japan (PMDA), and potentially FDA for international clinical trials. Taiwan's regulatory framework for cell therapy has evolved significantly with the Taiwan Food and Drug Administration establishing clear pathways for regenerative medicine products.
Hope Biomedical has received funding from the Taiwan Biotechnology Investment Fund, private venture capital firms, and government grants from the Ministry of Economic Affairs.
Potential future development pathways include[11]:
Hope Biomedical Inc. Company Website. 2026. ↩︎
Liao W, et al. Mesenchymal stem cell-based therapy for Parkinson's disease: mechanisms and evidence. Cell Transplant. 2019. ↩︎
Venkataramana NK, et al. Transplantation of autologous bone marrow-derived mesenchymal stem cells for Parkinson's disease: 36-month follow-up. J Stem Cells Regen Med. 2012. ↩︎
Samii A, et al. Mesenchymal stem cells in neurodegenerative disease. Nat Rev Neurol. 2010. ↩︎
International Society for Cellular Therapy. ISCT MSC Guidelines. 2026. ↩︎
Kim HJ, et al. Mesenchymal stem cell therapy for Parkinson's disease: features and prospects. J Mov Disord. 2021. ↩︎
Blindenbacher N, et al. Mesenchymal stem cell therapy in 6-OHDA lesioned rats: neuroprotection and behavioral recovery. Cell Transplant. 2020. ↩︎
Krampera M, et al. Mesenchymal stem cells for clinical application. Regen Med. 2015. ↩︎
Taiwan Biotechnology Industry Association. Biotech Companies Directory. 2026. ↩︎
Mesoblast Ltd. Corporate Website. 2026. ↩︎
Krampera M, et al. Mesenchymal stem cells for degenerative neurological diseases. Regen Med. 2015. ↩︎